AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36471257
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant therapy (no therapy)
Trial: 33773120
Drug: Riociguat (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat (up to 2.5 mg three times per day)
Trial: 33773120
Drug: PDE5i (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDE5i (oral sildenafil [≥60 mg per day] or oral tadalafil [20–40 mg per day])
Trial: 32546647
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint blockade (ICB) therapy
Trial: 32546647
Drug: IDO enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDO enzyme inhibitor treatment
Trial: 33580944
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (30 mg/kg, six doses each 5 mg/kg, biweekly for 3 weeks)
Trial: 33580944
Drug: Miltefosine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miltefosine (2.5 mg/kg or 100 mg/day for 12 weeks)
Trial: 35925752
Drug: 1.8 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mg/day liraglutide
Trial: 32828393
Drug: Biotin supplementation
RxNorm normalized name: Biotin
DrugBank: Biotin (DB00121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biotin supplementation at 0.3 mg/L (T1) and 0.45 mg/L (T2) in drinking water for older hens (53-56 weeks)
Trial: 33167773
Drug: Metformin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2 g/day)
Trial: 32092343
Drug: High-dose-rate brachytherapy
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose-rate brachytherapy boost (HDRB)
Trial: 32092343
Drug: 66 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 66 Gy external beam radiation therapy (EBRT)
Trial: 32092343
Drug: 70 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 Gy external beam radiation therapy (EBRT)
Trial: 32092343
Drug: 74 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 74 Gy external beam radiation therapy (EBRT)
Trial: 36184124
Drug: Carotegrast methyl
RxNorm normalized name: Carotegrast methyl
DrugBank: Carotegrast methyl (DB16119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotegrast methyl 480 mg
Trial: 36184124
Drug: Carotegrast methyl
RxNorm normalized name: Carotegrast methyl
DrugBank: Carotegrast methyl (DB16119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotegrast methyl 960 mg
Trial: 32797382
Drug: Universal HIV
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal HIV testing and treatment (UTT) including home-based and mobile testing, active linkage to care, rapid ART start, and enhanced male circumcision services.
Trial: 35775502
Drug: Universal HIV
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal HIV testing and treatment (UTT)
Trial: 35997234
Drug: L-menthol ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-menthol ingestion (M-IG)
Trial: 35997234
Drug: L-menthol mouth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-menthol mouth rinsing (M-MR)
Trial: 32192644
Drug: Alirocumab (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (75 or 150 mg every 2 weeks)
Trial: 35236763
Drug: Lung volume
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung volume recruitment (LVR) twice daily for 2 years
Trial: 35140347
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of the µ‐opioid agonist morphine sulfate
Trial: 35974938
Drug: Levetiracetam (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (1000 mg)
Trial: 35974938
Drug: Lamotrigine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (250 mg)
Trial: 33689731
Drug: Midodrine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (5 mg TDS, up-titrated to 30 mg/day after one week)
Trial: 33689731
Drug: Fludrocortisone (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone (0.05 mg BD, up-titrated to 0.2 mg/day after one week)
Trial: 32930386
Drug: Low-dose computed
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose computed tomography (n = 2029)
Trial: 32179023
Drug: Multimodal intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimodal intervention to improve vaccination rates including designation of an immunization champion, purchasing vaccines, guidance on storage and management, routine identification of eligible patients, standing orders for vaccination, and vaccine administration.
Trial: 33594386
Drug: Sublingual apomorphine
RxNorm normalized name: apomorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual apomorphine hydrochloride film (APL‐130277, Kynmobi) administered up to 5 times a day
Trial: 35850436
Drug: Lithothamnion (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithothamnion (100 mg/kg bw PO BID) for 7 days before oligofructose intake (10 g/kg PO)
Trial: 35872954
Drug: Overall oral
RxNorm normalized name: Feverall Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall oral care (observation group)
Trial: 35872954
Drug: Basic oral
RxNorm normalized name: sodium phosphate, dibasic Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic oral care (control group)
Trial: 38183804
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy for insomnia (CBT-I)
Trial: 34692725
Drug: Silybin-phospholipids complex
RxNorm normalized name: silybin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silybin-phospholipids complex (303 mg), 10 μg of vitamin D, and 15 mg of vitamin E twice a day for 6 months (wild type treated group)
Trial: 34692725
Drug: Silybin-phospholipids complex
RxNorm normalized name: silybin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silybin-phospholipids complex (303 mg), 10 μg of vitamin D, and 15 mg of vitamin E twice a day for 6 months (mutated treated group)
Trial: 34181714
Drug: cPass neutralization
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cPass neutralization antibody assay
Trial: 32118260
Drug: Self-reported daily
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported daily abstinence
Trial: 33836800
Drug: ChemoRadiation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChemoRadiation and Immunotherapy (CRIO) with durvalumab (anti-PD-L1 checkpoint inhibitor)
Trial: 35469779
Drug: Auditory, tactile,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auditory, tactile, visual, and vestibular with odor from a baby lotion (ATVVO)
Trial: 38345741
Drug: Levodopa-carbidopa intestinal
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa-carbidopa intestinal gel (LCIG)
Trial: 33093598
Drug: Levodopa-entacapone-carbidopa intestinal
RxNorm normalized name: carbidopa / entacapone / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa-entacapone-carbidopa intestinal gel (LECIG)
Trial: 33989106
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (20 µg) of recombinant hepatitis B vaccine
Trial: 33989106
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (60 µg) of recombinant hepatitis B vaccine
Trial: 32951731
Drug: Intravenous Gamma
RxNorm normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Gamma Globulin (IVIG)
Trial: 32441833
Drug: L-arginine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (5 g)
Trial: 32441833
Drug: Tadalafil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (5 mg)
Trial: 32441833
Drug: Combined L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined L-arginine (5 g) with tadalafil (5 mg)
Trial: 32346743
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy with motor imagery (MI) principles
Trial: 34564686
Drug: Topical dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dexamethasone 2mg/5ml
Trial: 34564686
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine 100mg/ml
Trial: 32353115
Drug: Cosyntropin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cosyntropin (70 μg/hour for 2.5 hours)
Trial: 35943903
Drug: Online peer
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online peer support intervention based on acceptance and commitment therapy
Trial: 34481070
Drug: Computer-generated smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-generated smoking cessation pharmacotherapy recommendation algorithm integrated into HIV primary care
Trial: 36332361
Drug: Standard-of-care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (SOC) with paracetamol
Trial: 35527651
Drug: Stimunex® gocce
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimunex® gocce (food supplement) given daily for 4 months
Trial: 35527651
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for respiratory infections (Control group)
Trial: 35527651
Drug: Stimunex® gocce
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimunex® gocce (food supplement)
Trial: 35410930
Drug: Reusable catheters
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reusable catheters replaced every 2 weeks and cleaning solution replaced every 24 hours
Trial: 34226231
Drug: Daily patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily patient contact
Trial: 32856272
Drug: Single RAS
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single RAS blocker therapy
Trial: 32856272
Drug: Dual RAS
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual RAS blocker therapy
Trial: 32856272
Drug: Both single
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both single and dual RAS blocker therapy
Trial: 32118792
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (t=0) - teeth extracted without orthodontic treatment
Trial: 33914319
Drug: TachoSil (collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TachoSil (collagen patches coated with human coagulation factors)
Trial: 33970657
Drug: Dynamic therapy
RxNorm normalized name: AVOBENZONE 3 g in 100 mL / OCTINOXATE 7.5 g in 100 mL / OCTISALATE 5 g in 100 mL / OXYBENZONE 6 g in 100 mL TOPICAL LOTION [PHOTO DYNAMIC THERAPY SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic therapy
Trial: 35337389
Drug: Lifestyle advice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle advice with or without metformin
Trial: 33789580
Drug: Quetiapine 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 12.5 mg once daily at bedtime for a maximum of 7 days
Trial: 33789580
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily at bedtime for a maximum of 7 days
Trial: 36133576
Drug: Task-based LSVT-BIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-based LSVT-BIG intervention (30 minutes of conventional occupational therapy and 40 minutes of task-based LSVT-BIG program, once a day, 5 times a week for 4 weeks)
Trial: 36133576
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (30 minutes of conventional occupational therapy and 40 minutes of relaxation and stretching, once a day, 5 times a week for 4 weeks)
Trial: 35198517
Drug: IBA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBA plus speech therapy
Trial: 35198517
Drug: IBA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBA plus inspiratory muscle training and speech therapy
Trial: 35198517
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (surgical)
Trial: 36280988
Drug: Manual lumbar
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual lumbar decompression, lumbar mobilisation, hot packs, TENS, and exercise therapy (Group A - acute)
Trial: 36280988
Drug: Lumbar mobilisation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar mobilisation, hot packs, and exercise therapy (Group C - control)
Trial: 36280988
Drug: Lumbar mobilisation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar mobilisation, hot packs, and exercise therapy (Group B - chronic)
Trial: 34677151
Drug: Zufa syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zufa syrup (7.5 mL every 4 hours for 10 days)
Trial: 34677151
Drug: Placebo syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syrup (identical-looking, 7.5 mL every 4 hours for 10 days)
Trial: 34677151
Drug: Zufa syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zufa syrup
Trial: 37304656
Drug: Movement meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Movement meditation (all doses)
Trial: 37304656
Drug: Sitting meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitting meditation (all doses)
Trial: 33103229
Drug: ACTH therapy
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH therapy
Trial: 35334969
Drug: Curcumin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (1000 mg) with ONS
Trial: 34932018
Drug: Scoring model
RxNorm normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scoring model based on risk factors (CgA, creatinine, previous chemotherapy)
Trial: 33001236
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg levosimendan
Trial: 35041042
Drug: Dexamethasone (0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.30 mg per kg/day, intravenous, twice daily for 3 days)
Trial: 34757600
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 U/mL with fasting plasma glucose (FPG) targets ≤ 5.6 mmol/L
Trial: 34757600
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 U/mL with fasting plasma glucose (FPG) targets ≤ 6.1 mmol/L
Trial: 34757600
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 U/mL with fasting plasma glucose (FPG) targets ≤ 7.0 mmol/L
Trial: 35485815
Drug: Oxidised dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxidised dextran (ANDROEXPERT SV1) suppositories, rectally once per day for 10 days, then every other day for 20 days.
Trial: 35485815
Drug: Placebo (cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cocoa butter) suppositories, rectally in a similar regimen.
Trial: 36123964
Drug: Codeine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine (60 mg/day for 2 weeks)
Trial: 36123964
Drug: Levodropropizine (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodropropizine (180 mg/day for 2 weeks)
Trial: 35286750
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C-G, 22 patients)
Trial: 36189778
Drug: Behavioral strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral strategies (e.g., prompting and rewards)
Trial: 33485454
Drug: BPD and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPD and RYGB (compared to medical therapy)
Trial: 32195954
Drug: Paraffin therapy
RxNorm normalized name: Paraffin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paraffin therapy (20 minutes)
Trial: 32195954
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no paraffin therapy)
Trial: 35147680
Drug: AmBisome monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmBisome monotherapy (40mg/kg intravenous liposomal amphotericin B administered in 8 equal doses over 24 days)
Trial: 35147680
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (30mg/kg intravenous liposomal amphotericin B administered in 6 equal doses over 24 days + 1.4g oral miltefosine administered in two daily doses of 50mg over 14 days)
Trial: 35147680
Drug: AmBisome monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmBisome monotherapy (excluding those with concurrent tuberculosis)
Trial: 35147680
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (excluding those with concurrent tuberculosis)
Trial: 33382101
Drug: Platelet-rich fibrin
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich fibrin (PRF) as an adjunct to scaling and root planing (ScRp)
Trial: 34993386
Drug: Aspirin-sensitive patients
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin-sensitive patients
Trial: 34993386
Drug: Aspirin-resistant patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin-resistant patients
Trial: 33119948
Drug: 300 g
RxNorm normalized name: Zantac 300 GELdose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 g day‐1 RS‐enriched potatoes (approximately two potatoes; 18 g RS)
Trial: 33026166
Drug: BACPPI (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BACPPI (20 mg of rabeprazole, 1000 mg of amoxicillin, 500 mg of clarithromycin, and 220 mg of bismuth potassium citrate) for 10 days
Trial: 33026166
Drug: BACPPI (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BACPPI (20 mg of rabeprazole, 1000 mg of amoxicillin, 500 mg of clarithromycin, and 220 mg of bismuth potassium citrate) for 14 days
Trial: 32639057
Drug: Royal Jelly
RxNorm normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Royal Jelly 100 mg kg‐1 BW‐1 (RJ100)
Trial: 32639057
Drug: Royal Jelly
RxNorm normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Royal Jelly 200 mg kg‐1 BW‐1 (RJ200)
Trial: 32129161
Drug: Darunavir-ritonavir (DRV/r)
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darunavir-ritonavir (DRV/r) plus rilpivirine (RPV) once daily (QD)
Trial: 34907523
Drug: Ultrasound-guided multiple-injection
RxNorm normalized name: sodium acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided multiple-injection costotransverse block (MICB) with three injections of 10 ml of ropivacaine (5 mg/ml)
Trial: 34907523
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with three injections of 10 ml of saline (0.9%)
Trial: 34907523
Drug: Ultrasound-guided multiple-injection
RxNorm normalized name: sodium acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided multiple-injection costotransverse block (MICB)
Trial: 32957332
Drug: Shexiang Tongxin
RxNorm normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shexiang Tongxin dropping pill (STDP)
Trial: 33393630
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g fish oil/day (1.1 g eicosapentaenoic acid (EPA) + 0.8 g DHA)
Trial: 33393630
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g corn oil/day (placebo)
Trial: 32850414
Drug: IMRT combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT combined with concurrent cisplatin (CCRT group)
Trial: 32652092
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline 0.9%) spray
Trial: 34826225
Drug: Ritlecitinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib (oral JAK3-selective inhibitor)
Trial: 37203336
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance
Trial: 32721994
Drug: Pre- and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre- and postprandial levels of insulin, leptin, glucose, and ghrelin
Trial: 33404656
Drug: Febuxostat (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (40 mg/day)
Trial: 34213870
Drug: Ozone/oxygen injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone/oxygen injection (25 mu-g/mL in 20 mL)